Donna Salzman
Overview
Explore the profile of Donna Salzman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parks K, Diebold K, Salzman D, Di Stasi A, Al-Kadhimi Z, Espinoza-Gutarra M, et al.
EJHaem
. 2024 Jun;
5(3):560-564.
PMID: 38895080
Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low-dose decitabine...
2.
Kidwell K, Bal S, Godby K, Ravi G, Costa L, Shrestha S, et al.
Transplant Cell Ther
. 2024 Jun;
30(11):1086.e1-1086.e7.
PMID: 38876427
Increasing number of older adults with Plasma Cell Disorders (PCDs) are receiving autologous stem cell transplant (ASCT) in the US. Hospital associated disability (HAD) is a common complication associated with...
3.
Jamy O, Diebold K, Davis K, Bachiashvili K, Rangaraju S, Vachhani P, et al.
Bone Marrow Transplant
. 2023 Apr;
58(7):823-825.
PMID: 37012416
No abstract available.
4.
McDonald A, Dai C, Meng Q, Hageman L, Richman J, Wu J, et al.
JAMA Oncol
. 2023 Jan;
9(3):376-385.
PMID: 36656600
Importance: Survivors of blood or marrow transplant (BMT) are at increased risk of subsequent malignant neoplasms (SMNs). Cancers of the gastrointestinal (GI) system are of special interest because their clinical...
5.
Jamy O, Dasher J, Chen A, Salzman D, Bhatia R, Bhatia S
Bone Marrow Transplant
. 2022 Dec;
58(3):311-316.
PMID: 36509918
Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-hsct) can require intensive care unit (ICU) admission in the post-transplant period. Whereas outcomes of ICU admission are poor, little is known about...
6.
Falcon C, Smith L, Al-Obaidi M, Abu Zaanona M, Purvis K, Minagawa K, et al.
Front Immunol
. 2022 Oct;
13:975233.
PMID: 36189285
Gene-modified cellular therapies carry inherent risks of severe and potentially fatal adverse events, including the expansion of alloreactive cells or malignant transformation due to insertional mutagenesis. Strategies to mitigate uncontrolled...
7.
Zainaldin C, Arora S, Bathini S, Gupta U, Pandya V, Bae S, et al.
Leuk Lymphoma
. 2022 Sep;
63(13):3245-3248.
PMID: 36107006
No abstract available.
8.
Jamy O, Arora S, Meredith R, Salzman D, Di Stasi A, Minagawa K, et al.
Bone Marrow Transplant
. 2022 Jul;
57(10):1597-1599.
PMID: 35810256
No abstract available.
9.
Armenian S, Chen Y, Hageman L, Wu J, Landier W, Bosworth A, et al.
J Clin Oncol
. 2022 Jun;
40(28):3278-3288.
PMID: 35731989
Purpose: Blood or marrow transplantation (BMT) is an integral part of consolidation and/or salvage therapy for patients with acute myeloid leukemia (AML). With the growing population of AML survivors, there...
10.
Arora S, Zainaldin C, Bathini S, Gupta U, Worth S, Bachiashvili K, et al.
Leuk Res
. 2022 Apr;
117:106844.
PMID: 35487134
Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia...